ArticleMarine drugs2022
Insights into the Antimicrobial Activities and Metabolomes of
Article in Marine drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Contrasting Coastal Environments Are Associated With Ecotype-Specific Leaf Polyphenolic Profiles and Bioactivity in Corema album subsp. album.Chemistry & biodiversity · 2026Article
- Cryptic Interactions in a Marine Microcosm: Sponges Shape the Microbiome of a Resident Goby.Molecular ecology · 2026Article
- Exploring the Environmental Resistome and Bacterial Novelty in Marine Isolates from the North Portuguese Coast.Antibiotics (Basel, Switzerland) · 2026Article
- Respiratory bacteriome and its predicted functional profiles in blue whales (Balaenoptera musculus).Scientific reports · 2025Article
- Identification of a Pair of Linear or Cyclic Naturally Inspired Bifunctional Lipopeptide Antibiotics That Overcome Antimicrobial Resistance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Bioactivity and Chemical Profiling of the Sea-Ice MicroalgaBiomolecules · 2025Article
- An artificial selection procedure enriches for known and suspected chitin degraders from the prokaryotic rare biosphere of multiple marine biotopes.BMC microbiology · 2025Article
- A genomic view of the bacterial family Endozoicomonadaceae in marine symbioses.Communications biology · 2025Review
- Effects of ciprofloxacin on bacterial abundance and enrichments in samples taken from the sea surface microlayer and underlying waters in the southern North Sea.Frontiers in microbiology · 2025Article
- Draft genome sequence ofMicrobiology resource announcements · 2024Article
- Exploring the roles of ribosomal peptides in prokaryote-phage interactions through deep learning-enabled metagenome mining.Microbiome · 2024Article
- Bioprospection of the Antarctic DiatomsMarine drugs · 2024Article
- Natural product biosynthetic potential reflects macroevolutionary diversification within a widely distributed bacterial taxon.mSystems · 2023Article
- Article
- Long-read sequencing reveals the shell microbiome of apparently healthy American lobstersFrontiers in microbiology · 2023Article
- Marine Sponge and Octocoral-Associated Bacteria Show Versatile Secondary Metabolite Biosynthesis Potential and Antimicrobial Activities against Human Pathogens.Marine drugs · 2022Article
- Bioprospecting for Novel Bacterial Sources of Hydrolytic Enzymes and Antimicrobials in the Romanian Littoral Zone of the Black Sea.Microorganisms · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Two novel natural products, the polyketide cuniculene and the peptide antibiotic aquimarin, were recently discovered from the marine bacterial genus Aquimarina. However, the diversity of the secondary metabolite biosynthetic gene clusters (SM-BGCs) in Aquimarina genomes indicates a far greater biosynthetic potential. In this study, nine representative Aquimarina strains were tested for antimicrobial activity against diverse human-pathogenic and marine microorganisms and subjected to metabolomic and genomic profiling. We found an inhibitory activity of most Aquimarina strains against Candida glabrata and marine Vibrio and Alphaproteobacteria species. Aquimarina sp. Aq135 and Aquimarina muelleri crude extracts showed particularly promising antimicrobial activities, amongst others against methicillin-resistant Staphylococcus aureus. The metabolomic and functional genomic profiles of Aquimarina spp. followed similar patterns and were shaped by phylogeny. SM-BGC and metabolomics networks suggest the presence of novel polyketides and peptides, including cyclic depsipeptide-related compounds. Moreover, exploration of the ‘Sponge Microbiome Project’ dataset revealed that Aquimarina spp. possess low-abundance distributions worldwide across multiple marine biotopes. Our study emphasizes the relevance of this member of the microbial rare biosphere as a promising source of novel natural products. We predict that future metabologenomics studies of Aquimarina species will expand the spectrum of known secondary metabolites and bioactivities from marine ecosystems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.